Top

BMC Cancer

Published in:

Open Access 01-12-2008 | Research article

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Authors: Lifeng Wang, Jia Wei, Xiaoping Qian, Haitao Yin, Yang Zhao, Lixia Yu, Tingting Wang, Baorui Liu

Published in: BMC Cancer | Issue 1/2008

Abstract

Background

One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer susceptibility gene 1). To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/or docetaxel chemosensitivity.

Methods

Real-time quantitative PCR is used to analysis related genes expression in forty-six malignant effusions prospectively collected from non-small cell lung cancer (NSCLC), gastric and gynecology cancer patients. Viable tumor cells obtained from malignant effusions are tested for their sensitivity to cisplatin and docetaxel using ATP-TCA assay.

Results

ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC patients (P = 0.001). In NSCLC and gastric group, BRCA1 expression level is negatively correlated with the sensitivity to cisplatin (NSCLC: P = 0.014; gastric: P = 0.002) while positively correlated with sensitivity to docetaxel (NSCLC: P = 0.008; gastric: P = 0.032). A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n = 45).

Conclusion

Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients. And combination of ERCC1 and BRCA1 may have a better role on predicting the sensitivity to cisplatin than the single one is considered.

Available only for authorised users

Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O: Application of genomics in NSCLC. Lung Cancer. 2005, S33-40. 10.1016/S0169-5002(05)81571-5. Suppl 2

Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005, 10: 104-11. 10.1634/theoncologist.10-2-104.CrossRefPubMed

Mehlen P, Puisieux A: Metastasis: a question of life or death. Nature Rev Cancer. 2006, 6 (6): 449-58. 10.1038/nrc1886.CrossRef

Christofori G: New signals from the invasive front. Nature. 2006, 441: 444-50. 10.1038/nature04872.CrossRefPubMed

Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B: Expression of xeroderma pigmentosum a protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005, 103 (11): 2313-19. 10.1002/cncr.21031.CrossRefPubMed

Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res. 2000, 6: 4797-4802.PubMed

Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncology. 2005, 16 (10): 1646-1653. 10.1093/annonc/mdi316.CrossRef

Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groschen S, Cohen H, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol. 1996, 14: 176-82.PubMed

Vogel U, Dybdahl M, Frentz G, Nexo BA: DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 2000, 461: 197-210.CrossRefPubMed

10.

Kwon HC, Roh M, Oh S, Kim SH, Kim M, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007, 18: 504-9. 10.1093/annonc/mdl430.CrossRefPubMed

11.

Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Eng J Med. 2006, 335 (10): 983-991. 10.1056/NEJMoa060570.CrossRef

12.

Park DJ, Lenz HJ: Determination of chemosensitivity in gastric cancer. Curr Opin Pharmacol. 2006, 6: 337-344. 10.1016/j.coph.2006.05.002.CrossRefPubMed

13.

Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63: 6221-8.PubMed

14.

Rosell R, Cecere F, Santarpia M, Reguart N, Taron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006, 6: 323-331. 10.1016/j.coph.2006.01.011.CrossRefPubMed

15.

Mullan PB, Quinn JE, Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 2006, 25: 5854-63. 10.1038/sj.onc.1209872.CrossRefPubMed

16.

Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Nat Cancer Inst. 2004, 96: 1659-68.CrossRefPubMed

17.

Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004, 13: 2443-9. 10.1093/hmg/ddh260.CrossRefPubMed

18.

Kennedy RD, Quinn JE, Johnston PG, Harkin DP: BRCA1: mechanisms of inactivation and implications for management of patients. Lancet. 2002, 360: 1007-14. 10.1016/S0140-6736(02)11087-7.CrossRefPubMed

19.

Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H: Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 2006, 26: 695-702.PubMed

20.

Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995, 55: 5276-82.PubMed

21.

Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U, Dermatologic Cooperative Oncology Group: In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group. Clin Cancer Res. 2006, 12: 5454-63. 10.1158/1078-0432.CCR-05-2763.CrossRefPubMed

22.

Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, amont A, Gulliford T, Hurren J, Yiangou C, Cree IA: Cancer cell adaptation to chemotherapy. BMC Cancer. 2005, 5: 78-10.1186/1471-2407-5-78.CrossRefPubMedPubMedCentral

23.

Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human cancer cells. J Bio Chem. 1998, 273 (36): 23419-23425. 10.1074/jbc.273.36.23419.CrossRef

24.

Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B: Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat. 2005, 94: 71-80. 10.1007/s10549-005-7328-3.CrossRefPubMed

25.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006, 95: 1390-5. 10.1038/sj.bjc.6603428.CrossRefPubMedPubMedCentral

26.

Neragi-Miandoab S: Malignant pleural effusion. Current and evolving approaches for its diagnosis and management. Lung cancer. 2006, 54: 1-9. 10.1016/j.lungcan.2006.04.016.CrossRefPubMed

27.

Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG: Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer. 2007, 96: 241-7. 10.1038/sj.bjc.6603538.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/97/prepub

Title: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel
Authors: Lifeng Wang
Jia Wei
Xiaoping Qian
Haitao Yin
Yang Zhao
Lixia Yu
Tingting Wang
Baorui Liu
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-8-97

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Peripheral pulmonary nodules: Relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression

Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells

Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia

Expression analysis of carbohydrate antigens in ductal carcinoma in situof the breast by lectin histochemistry

Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: A historic prospective study

In silico analysis and verification of S100 gene expression in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer